To examine whether it is safe to continue low-dose (100 mg/day) aspirin perioperatively as a part of standard multimodal venous thromboembolic prophylaxis for total hip arthroplasty (THA) or total knee arthroplasty (TKA). Methods. 79 women and 60 men aged 52 to 91 years who underwent THA (n=50) or TKA (n=89) were prospectively studied. Preoperatively, 63 of the patients were on 100 mg of aspirin every morning for various medical reasons and continued in the perioperative period, except for the operation day. The remaining 76 patients were controls. Pre-and post-operative haemoglobin levels, postoperative blood drainage, and the amount of reinfused drained blood were recorded. Intra-operative blood loss and operative times were recorded for THA only. These parameters for the aspirin and control groups were compared. results. All the parameters, namely blood loss (intraoperative and postoperative), operative time, surgical Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthoplasty
wound healing, and drop in the haemoglobin level (determined on day 3) did not differ significantly between the 2 groups. conclusion. It is safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis.
Key words: arthroplasty, replacement, hip; arthroplasty, replacement, knee; aspirin; complications; perioperative period; safety; thromboembolism introduction Thromboembolism following joint arthroplasty is a common complication and can result in morbidity and mortality. The optimal prophylactic treatment for thromboembolism remains controversial. Our hospital's thromboprophylaxis protocol has entailed a combination of mechanical (sequential compression device plus TED stockings) and chemical prophylaxis (enoxaparin sodium 40 mg/day subcutaneously). The role of aspirin is controversial and perceived to contribute to complications such as bleeding, haematoma formation, delayed wound healing, and infection. 1, 2 Aspirin has been used for treating common health problems (fever, headaches, and arthritis) as well as cardiovascular and cerebrovascular insults (myocardial infarction and stroke), and as thromboprophylaxis following cardiac stent procedures. Discontinuing the drug perioperatively has been advocated to minimise the risk of complications (postoperative bleeding, haematoma formation, wound breakdown, and infection). We examined whether it was safe to continue lowdose (100 mg/day) aspirin perioperatively as a part of standard multimodal venous thromboembolic prophylaxis for total hip arthroplasty (THA) or total knee arthroplasty (TKA).
Materials and Methods
Between 2008 and 2010, 79 women and 60 men aged 52 to 91 years who underwent THA (n=50) or TKA (n=89) were prospectively studied. Patients undergoing bilateral or revision arthroplasty were excluded, as were those with previous thromboembolic episode to minimise confounding factors. Preoperatively, 63 of the patients were on 100 mg of aspirin every morning for various medical reasons and continued in the perioperative period, except for the operation day. The remaining 76 patients were controls.
For TKA, a medial peri-patellar approach was used. A Depuy uncemented Duofix tibial tray with a PFC Sigma cementless femoral component and a cemented, all-polyethylene patellar component were used. For THA, a posterior capsular sparing mini-invasive approach was used. A hydroxyapatitecoated, cementless, press-fit, Depuy Pinnacle Sector acetabular socket and a Groupe Lepine MBA hydroxyapatite-coated, uncemented, anatomic stem with an alumina-on-alumina bearing were used.
The pre-and post-operative haemoglobin levels, postoperative blood drainage, and the amount of reinfused drained blood were recorded. Intraoperative blood loss and operative times were recorded for THA only, as there was no intra-operative blood loss for TKA with the use of a tourniquet. Infection, bleeding, bruising, haematoma, prolonged wound drainage, and other wound complications were measured using the subjective rating scale (Table  1 ). 3 The differences between groups were compared using the Student's t test. 
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results
The mean preoperative haemoglobin level was not significantly different in the control and aspirin groups, even after subdivision according to gender ( Table 2 ). The mean postoperative blood drainage, the mean drop in haemoglobin level (determined on postoperative day 3), and the mean intra-operative blood loss and the operative time (for THA only) were not significantly different in the 2 groups, irrespective of gender (Table 2) . Three patients in each group developed deep vein thrombosis as diagnosed by duplex ultrasonography on postoperative day 5. All the thromboses were in the distal calf veins and of a non-occlusive nature. All patients received routine thromboprophylaxis (sequential compression device plus TED stockings and enoxaparin sodium 40 mg/day subcutaneously) for 5 days to 2 weeks during their hospital stay. In addition, the aspirin group received aspirin 100 mg/ day. After discharge from the hospital, both groups received aspirin 100 mg/day until their first followup at week 6. All thromboses resolved spontaneously. No patient had pulmonary emboli. One patient in each group developed superficial wound infection, which was treated with oral antibiotics for one week. No patients had wound dehiscences or other complications.
discussion
Aspirin inhibits the enzyme cyclooxygenase (COX) and therefore the production of prostaglandins. 4 There are 2 COX isoenzymes: COX-1 (the constitutive form) and COX-2 (the inducible form). In platelets, the COX-1 enzyme produces a prostanoid called thromboxane A2, which causes platelets to activate and aggregate. Aspirin inhibits the COX-1 enzyme and therefore the production of thromboxane A2. This confers a potential antiplatelet effect, which lasts for the life of the enucleated platelet (approximately 7 to 10 days).
Some studies suggest that aspirin leads to more bleeding, 1,2 but others disagree. 3, 5, 6 Aspirin has been reported to reduce the frequency of venous thrombosis, pulmonary embolism, and occlusive arterial events. [7] [8] [9] Its cessation before surgery has been thought to increase the risk of acute cardiovascular syndromes. 10 Our study confirmed that it was safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis. The intra-operative blood loss (for THA only) was slightly higher in the aspirin than control groups. This may be due to other confounding factors such as body habitus, length of incision, blood pressure, and type of anaesthesia.
The limitation of our study was a small sample size and non-randomisation of patients. This might have resulted in selection bias and low statistical power. A randomised control trial with a larger sample size is needed to confirm our results.
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